DOP2013000194A - Imidazo[5,1-f][1,2,4] triazinas para el tratamiento de trastornos neurologicos - Google Patents
Imidazo[5,1-f][1,2,4] triazinas para el tratamiento de trastornos neurologicosInfo
- Publication number
- DOP2013000194A DOP2013000194A DO2013000194A DO2013000194A DOP2013000194A DO P2013000194 A DOP2013000194 A DO P2013000194A DO 2013000194 A DO2013000194 A DO 2013000194A DO 2013000194 A DO2013000194 A DO 2013000194A DO P2013000194 A DOP2013000194 A DO P2013000194A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- treatment
- triazins
- imidazo
- compounds
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a compuestos de Fórmula y a sales de los mismos farmacéuticamente aceptables, a procedimientos para la preparación de, intermedios usados en la preparación de, y composiciones contentivas de dichos compuestos y a los usos de dichos compuestos en la fabricación de medicamentos para el tratamiento de una enfermedad o afección seleccionada del grupo que consiste en trastornos del sistema nervioso central, trastornos cognitivos, esquizofrenia, demencia y otros trastomos, en un mamífero.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161445617P | 2011-02-23 | 2011-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2013000194A true DOP2013000194A (es) | 2014-01-31 |
Family
ID=45755439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2013000194A DOP2013000194A (es) | 2011-02-23 | 2013-08-23 | Imidazo[5,1-f][1,2,4] triazinas para el tratamiento de trastornos neurologicos |
Country Status (30)
Country | Link |
---|---|
US (2) | US8598155B2 (es) |
EP (1) | EP2681218A1 (es) |
JP (1) | JP5543039B2 (es) |
KR (1) | KR101548443B1 (es) |
CN (1) | CN103391941A (es) |
AP (1) | AP2013007070A0 (es) |
AR (1) | AR085304A1 (es) |
AU (1) | AU2012221828C1 (es) |
BR (1) | BR112013021366A2 (es) |
CA (1) | CA2825699A1 (es) |
CL (1) | CL2013002125A1 (es) |
CO (1) | CO6751271A2 (es) |
CR (1) | CR20130371A (es) |
CU (1) | CU20130107A7 (es) |
DO (1) | DOP2013000194A (es) |
EA (1) | EA022586B1 (es) |
EC (1) | ECSP13012892A (es) |
GT (1) | GT201300206A (es) |
IL (1) | IL227716A0 (es) |
MA (1) | MA34922B1 (es) |
MX (1) | MX2013009684A (es) |
NI (1) | NI201300071A (es) |
PE (1) | PE20140236A1 (es) |
SG (1) | SG192576A1 (es) |
TN (1) | TN2013000349A1 (es) |
TW (1) | TWI469983B (es) |
UA (1) | UA106692C2 (es) |
UY (1) | UY33916A (es) |
WO (1) | WO2012114222A1 (es) |
ZA (1) | ZA201306348B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG192576A1 (en) * | 2011-02-23 | 2013-09-30 | Pfizer | IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神***病を処置するための方法および組成物 |
AU2014261070A1 (en) * | 2013-05-02 | 2015-10-29 | Pfizer Inc. | Imidazo-triazine derivatives as PDE10 inhibitors |
US9815796B2 (en) | 2013-12-23 | 2017-11-14 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as PDE2 inhibitors |
WO2015106032A1 (en) | 2014-01-08 | 2015-07-16 | Intra-Cellular Therapies, Inc. | Products and pharmaceutical compositions |
PL3597649T3 (pl) * | 2014-04-23 | 2022-04-04 | Dart Neuroscience Llc | Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2 |
EP3215508A1 (en) | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituted 5-methyl-[1, 2, 4]triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors |
WO2016090380A1 (en) | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Organic compounds |
MX2017007377A (es) | 2014-12-06 | 2017-11-06 | Intra-Cellular Therapies Inc | Compuestos organicos. |
CN104525240A (zh) * | 2014-12-10 | 2015-04-22 | 河北工业大学 | 硝酸铁作为催化剂在苯与羟胺盐反应一步法制苯胺反应中的应用方法 |
WO2016103097A1 (en) | 2014-12-22 | 2016-06-30 | Pfizer Inc. | Antagonists of prostaglandin ep3 receptor |
TWI713497B (zh) * | 2015-02-26 | 2020-12-21 | 南韓商愛思開生物製藥股份有限公司 | 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物 |
WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
WO2016154081A1 (en) | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
EP3291817B1 (en) | 2015-05-05 | 2019-10-02 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as pde2 inhibitors |
WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
WO2016209749A1 (en) | 2015-06-25 | 2016-12-29 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |
WO2017004134A1 (en) * | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017000276A1 (en) * | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
UA122423C2 (uk) | 2015-11-02 | 2020-11-10 | Янссен Фармацевтика Нв | [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИН-7-ІЛЬНА СПОЛУКА |
CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
WO2018065288A1 (de) | 2016-10-07 | 2018-04-12 | Bayer Cropscience Aktiengesellschaft | 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz |
KR20190071721A (ko) | 2016-11-02 | 2019-06-24 | 얀센 파마슈티카 엔.브이. | Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물 |
JP7076441B2 (ja) | 2016-11-02 | 2022-05-27 | ヤンセン ファーマシューティカ エヌ.ベー. | PDE2阻害剤としての[1,2,4]トリアゾロ[1,5-a]ピリミジン誘導体 |
MX2019005123A (es) | 2016-11-02 | 2019-06-20 | Janssen Pharmaceutica Nv | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2. |
MX2019008229A (es) | 2017-01-10 | 2019-10-24 | Bayer Ag | Derivados heterociclicos como agentes de control de plagas. |
CN110312718B (zh) | 2017-01-10 | 2023-02-28 | 拜耳公司 | 作为害虫防治剂的杂环烯衍生物 |
CA3083176A1 (en) | 2017-11-23 | 2019-05-31 | Oslo University Hospital Hf | Treatment of tachycardia |
CN108640923A (zh) * | 2018-07-09 | 2018-10-12 | 湖南天地恒制药有限公司 | 一种托法替布关键中间体的制备方法 |
EP3870300A4 (en) * | 2018-10-23 | 2022-06-22 | Intra-Cellular Therapies, Inc. | NEW COMPOUNDS |
US11492362B1 (en) | 2022-02-17 | 2022-11-08 | King Abdulaziz University | Pyridine derivatives for the treatment of hyperproliferative diseases |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993012113A1 (en) * | 1991-12-17 | 1993-06-24 | The Upjohn Company | 3-SUBSTITUTED IMIDAZO (1,5-a) AND IMIDAZO (1,5-a)-TRIAZOLO (1,5-c) QUINOXALINES AND QUINAZOLINES WITH CNS ACTIVITY |
YU59100A (sh) * | 1999-10-11 | 2003-10-31 | Pfizer Inc. | Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera |
DE10130167A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
DE10230604A1 (de) * | 2002-07-08 | 2004-01-29 | Bayer Ag | Heterocyclisch substituierte Imidazotriazine |
DE10230605A1 (de) * | 2002-07-08 | 2004-01-29 | Bayer Ag | Substituierte Imidazotriazine |
WO2005041957A1 (en) * | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
SG163576A1 (en) | 2004-04-02 | 2010-08-30 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
AR053090A1 (es) * | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
DE102004038328A1 (de) * | 2004-08-06 | 2006-03-16 | Bayer Healthcare Ag | Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten |
DE602005023333D1 (de) * | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
AU2006204451C1 (en) * | 2005-01-05 | 2012-05-24 | Takeda Gmbh | Triazolophthalazines as PDE2-inhibitors |
ATE472543T1 (de) | 2005-01-07 | 2010-07-15 | Pfizer Prod Inc | Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren |
SI1951724T1 (sl) | 2005-11-17 | 2011-09-30 | Osi Pharmaceuticals Llc | Kondenzirani biciklični mTOR inhibitorji |
WO2007087395A2 (en) | 2006-01-25 | 2007-08-02 | Osi Pharmaceuticals, Inc. | UNSATURATED mTOR INHIBITORS |
US7651687B2 (en) | 2006-03-13 | 2010-01-26 | Osi Pharmaceuticals, Inc. | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors |
EP2526933B1 (en) | 2006-09-22 | 2015-02-25 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
JP2010532756A (ja) | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | mTORC1及びmTORC2の両方の阻害剤を含む組み合わせ抗癌療法 |
US7683575B2 (en) | 2007-07-18 | 2010-03-23 | Tesla Motors, Inc. | Method and apparatus for identifying and disconnecting short-circuited battery cells within a battery pack |
EP2276763A1 (en) | 2008-03-19 | 2011-01-26 | OSI Pharmaceuticals, Inc. | Mtor inhibitor salt forms |
EP2283020B8 (en) | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituted imidazopyr-and imidazotri-azines |
WO2011005909A2 (en) | 2009-07-09 | 2011-01-13 | Osi Pharmaceuticals, Inc. | Process for substituted 3-amino-5-oxo-4,5-dihydro-[1,2,4]triazines |
US8487096B2 (en) | 2010-02-03 | 2013-07-16 | Incyte Corporation | Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors |
SG192576A1 (en) * | 2011-02-23 | 2013-09-30 | Pfizer | IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
-
2012
- 2012-02-09 SG SG2013055298A patent/SG192576A1/en unknown
- 2012-02-09 EA EA201390971A patent/EA022586B1/ru not_active IP Right Cessation
- 2012-02-09 CA CA2825699A patent/CA2825699A1/en not_active Abandoned
- 2012-02-09 KR KR1020137024689A patent/KR101548443B1/ko not_active IP Right Cessation
- 2012-02-09 JP JP2013554958A patent/JP5543039B2/ja not_active Expired - Fee Related
- 2012-02-09 BR BR112013021366A patent/BR112013021366A2/pt not_active IP Right Cessation
- 2012-02-09 MX MX2013009684A patent/MX2013009684A/es not_active Application Discontinuation
- 2012-02-09 PE PE2013001976A patent/PE20140236A1/es not_active Application Discontinuation
- 2012-02-09 AP AP2013007070A patent/AP2013007070A0/xx unknown
- 2012-02-09 CN CN2012800101209A patent/CN103391941A/zh active Pending
- 2012-02-09 EP EP12705448.4A patent/EP2681218A1/en not_active Withdrawn
- 2012-02-09 AU AU2012221828A patent/AU2012221828C1/en not_active Ceased
- 2012-02-09 WO PCT/IB2012/050589 patent/WO2012114222A1/en active Application Filing
- 2012-02-09 UA UAA201309471A patent/UA106692C2/uk unknown
- 2012-02-20 TW TW101105525A patent/TWI469983B/zh not_active IP Right Cessation
- 2012-02-20 US US13/400,172 patent/US8598155B2/en active Active
- 2012-02-22 UY UY0001033916A patent/UY33916A/es not_active Application Discontinuation
- 2012-02-22 AR ARP120100575A patent/AR085304A1/es unknown
-
2013
- 2013-07-24 CL CL2013002125A patent/CL2013002125A1/es unknown
- 2013-07-29 IL IL227716A patent/IL227716A0/en unknown
- 2013-07-30 CU CU2013000107A patent/CU20130107A7/es unknown
- 2013-07-31 CR CR20130371A patent/CR20130371A/es unknown
- 2013-08-19 TN TNP2013000349A patent/TN2013000349A1/fr unknown
- 2013-08-22 GT GT201300206A patent/GT201300206A/es unknown
- 2013-08-22 CO CO13199523A patent/CO6751271A2/es unknown
- 2013-08-22 NI NI201300071A patent/NI201300071A/es unknown
- 2013-08-22 ZA ZA2013/06348A patent/ZA201306348B/en unknown
- 2013-08-23 MA MA36201A patent/MA34922B1/fr unknown
- 2013-08-23 DO DO2013000194A patent/DOP2013000194A/es unknown
- 2013-09-23 EC ECSP13012892 patent/ECSP13012892A/es unknown
- 2013-11-01 US US14/069,640 patent/US9200000B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2013000194A (es) | Imidazo[5,1-f][1,2,4] triazinas para el tratamiento de trastornos neurologicos | |
GT201300179A (es) | Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos | |
ECSP15006871A (es) | 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos | |
CR20140397A (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks | |
UY33245A (es) | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas | |
CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
CL2012000589A1 (es) | Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras. | |
UY32391A (es) | Compuestos amino-heterocíclicos | |
CL2009000975A1 (es) | Compuestos derivados de quinuclidina, ligandos del receptor de acetilcolina a7; su composicion farmaceutica; su uso para el tratamiento de trastornos del sistema nervioso central, en especial afectivos y neurodegenerativos, enfermedades tales como esquizofrenia y alzheimer. | |
CO6290683A2 (es) | Compuestos de pirido imidazolinas heterociclicas y sus composiciones como inhibidores de c-met | |
ECSP14013221A (es) | Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento. | |
DOP2014000265A (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
CU24327B1 (es) | Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden | |
BR112013020536A2 (pt) | 1,4-oxazepinas como inibidores de bace1 e/ou bace2 | |
UY33557A (es) | Inhibidores de oxadiazol de la produccion de leucotrieno | |
DOP2016000276A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
AR123407A1 (es) | Un proceso para la fabricación de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octahidro-[1,3]dioxolo[4,5:5,6]benzo[1,2-g]quinolina y (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolina-6,7-diol | |
BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
CO2017003305A2 (es) | Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa | |
ECSP14013155A (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
AR092247A1 (es) | INHIBIDORES DE LA b-SECRETASA | |
CU20160156A7 (es) | Compuestos de isoquinolinas 2-sustituidas o sus análogos que poseen hasta cinco átomos de carbono sustituidos por nitrógeno,útiles como ligandos de dopamina d1 | |
BR112018004347A2 (pt) | derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida | |
BR112014012031A2 (pt) | derivados de 3-fenil-isoquinolin-1(2h)-ona como inibidores de parp-1 | |
BR112015010512A2 (pt) | derivados de carboxamida de 3-aminociclopentano |